JVI Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Robert-Guroff, M.
Right arrow Articles by Sinangil, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Robert-Guroff, M.
Right arrow Articles by Sinangil, F.

Journal of Virology, December 1998, p. 10275-10280, Vol. 72, No. 12
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Vaccine Protection against a Heterologous, Non-Syncytium-Inducing, Primary Human Immunodeficiency Virus

Marjorie Robert-Guroff,1,* Harvinder Kaur,1 L. Jean Patterson,1 Michel Leno,1 Anthony J. Conley,2 Philip M. McKenna,2 Phillip D. Markham,3 Ersell Richardson,1 Kristine Aldrich,1 Kamalpreet Arora,1 Lalita Murty,1 Lucretia Carter,1 Susan Zolla-Pazner,4 and Faruk Sinangil5

Basic Research Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-42551; Merck Research Laboratories, West Point, Pennsylvania 194862; Advanced BioScience Laboratories, Inc., Kensington, Maryland 20895-10783; VA and NYU Medical Centers, New York, New York 100104; and Chiron Corporation, Emeryville, California 94608-29165

Received 29 June 1998/Accepted 9 September 1998

Vaccine-induced protection of chimpanzees against laboratory-adapted and syncytium-inducing, multiply passaged primary human immunodeficiency virus type 1 (HIV-1) isolates, but not against non-syncytium-inducing, minimally passaged ones, has been demonstrated. Following challenge with such an isolate, HIV-15016, we obtained complete protection in one of three chimpanzees previously protected against low- and high-dose HIV-1SF2 exposures after immunization with an adenovirus-HIV-1MN gp160 priming-HIV-1SF2 gp120 boosting regimen. At challenge, the protected chimpanzee exhibited broad humoral immunity, including neutralizing antibody activity. These results demonstrate the potential of this combination vaccine strategy and suggest that vaccine protection against an HIV isolate relevant to infection of people is feasible.

* Corresponding author. Mailing address: Basic Research Laboratory, National Cancer Institute, National Institutes of Health, Building 37, Room 6B03, Bethesda, MD 20892-4255. Phone: (301) 496-2114. Fax: (301) 496-8394. E-mail: guroffm{at}dc37a.nci.nih.gov.

Journal of Virology, December 1998, p. 10275-10280, Vol. 72, No. 12
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. Mol. Cell. Biol. Microbiol. Mol. Biol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 1998 by the American Society for Microbiology. All rights reserved.